Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/60513
Full metadata record
DC FieldValueLanguage
dc.creatorGuilherme Grossi Lopes Cançadopt_BR
dc.creatorLuciana Costa Fariapt_BR
dc.creatorElze Maria Gomes de Oliveirapt_BR
dc.creatorVivian Rotmanpt_BR
dc.creatorDaniel Ferraz de Campos Mazopt_BR
dc.creatorValéria Ferreira de Almeida e Borgespt_BR
dc.creatorLiliana Sampaio Costa Mendespt_BR
dc.creatorLiana Codespt_BR
dc.creatorMario Guimarães Pessoapt_BR
dc.creatorIzabelle Venturini Signorellipt_BR
dc.creatorCynthia Levypt_BR
dc.creatorCláudia Alves Coutopt_BR
dc.creatorPaulo Lisboa Bittencourtpt_BR
dc.creatorLaura Vilar Guedespt_BR
dc.creatorMichelle Harriz Bragapt_BR
dc.creatorDébora Raquel Benedita Terrabuiopt_BR
dc.creatorEduardo Luiz Rachid Cançadopt_BR
dc.creatorMaria Lucia Gomes Ferrazpt_BR
dc.creatorCristiane Alves Villela-Nogueirapt_BR
dc.creatorMateus Jorge Nardellipt_BR
dc.date.accessioned2023-11-06T20:34:27Z-
dc.date.available2023-11-06T20:34:27Z-
dc.date.issued2022-01-20-
dc.citation.volume12pt_BR
dc.citation.spage818089pt_BR
dc.citation.epage6pt_BR
dc.identifier.doihttps://doi.org/10.3389/fphar.2021.818089pt_BR
dc.identifier.issn1663-9812pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/60513-
dc.description.resumoAim: Up to 40% of patients with primary biliary cholangitis (PBC) will have a suboptimal biochemical response to ursodeoxycholic acid (UDCA), which can be improved by the addition of fibrates. This exploratory study aims to evaluate the long-term real-life biochemical response of different fibrates, including ciprofibrate, in subjects with UDCA-unresponsive PBC. Methods: The Brazilian Cholestasis Study Group multicenter database was reviewed to assess the response rates to UDCA plus fibrates in patients with UDCA-unresponsive PBC 1 and 2 years after treatment initiation by different validated criteria. Results: In total, 27 patients (100% women, mean age 48.9 ± 9.2 years) with PBC were included. Overall response rates to fibrates by each validated criterion varied from 39 to 60% and 39–76% at 12 and 24 months after treatment combination, respectively. Combination therapy resulted in a significant decrease in ALT and ALP only after 2 years, while GGT significantly improved in the first year of treatment. Treatment response rates at 1 and 2 years appear to be comparable between ciprofibrate and bezafibrate using all available criteria. Conclusion: Our findings endorse the efficacy of fibrate add-on treatment in PBC patients with suboptimal response to UDCA. Ciprofibrate appears to be at least as effective as bezafibrate and should be assessed in large clinical trials as a possibly new, cheaper, and promising option for treatment of UDCA-unresponsive PBC patients.pt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICApt_BR
dc.publisher.departmentMEDICINA - FACULDADE DE MEDICINApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofFrontiers in Pharmacologypt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectBezafibratept_BR
dc.subjectCiprofibratept_BR
dc.subjectFibratept_BR
dc.subjectPrimary biliary cholangitispt_BR
dc.subjectTreatment failurept_BR
dc.subjectUrsodeoxycholic acidpt_BR
dc.subject.otherFalha de Tratamentopt_BR
dc.subject.otherÁcidos Fíbricospt_BR
dc.subject.otherÁcido Ursodesoxicólicopt_BR
dc.subject.otherCirrose Hepática Biliarpt_BR
dc.subject.otherBezafibratopt_BR
dc.titleFibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Studypt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.frontiersin.org/articles/10.3389/fphar.2021.818089/fullpt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-3664-4839pt_BR
Appears in Collections:Artigo de Periódico



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.